S2Medical AB

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0011725084
SEK
0.01
0 (0.93%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About S2Medical AB stock-summary
stock-summary
S2Medical AB
Pharmaceuticals & Biotechnology
S2Medical AB (publ) is a Sweden-based medical technology company. The Company focuses on developing products for healing burns and chronic wounds, from debridement and granulation to reepithelialization. The Company's product portfolio includes INSTAQRETT, a sterile single-use mechanical debridement tool, the Epiprotect product line based on its collagen-mimicking Eiratex material, which includes EPIPROTECT Safestop, a blood-stilling membrane dressing, EPIPROTECT 2117, a synthetic substitute to allografts and xenografts, EPIPROTECT ULCER, dressing for treating ulcers, as well as INSTABIND bandages and Instagraft, a single-use medical device designed to treat chronic wounds with microtransplants from the patient's own skin without creating any new wounds. The Company is also the official distributor of Silverlon antimicrobial dressings for Nordic countries. In addition, it operates the S2Clinic, a wound healing center in Sweden.
Company Coordinates stock-summary
Company Details
Sunnorpsgatan 5 , LINKOPING None : 582 73
stock-summary
Tel: 46 8 7000050
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Amin Omrani
Independent Chairman of the Board
Mr. Marten Skog
Chief Operating Officer, Director
Mr. Martin Zetterstrom
Director
Mr. Carsten Browall
Independent Director
Mr. Roland Frosing
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
8 Million
(Quarterly Results - Dec 2024)
Net Profit:
-2 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 9 Million ()

stock-summary
P/E

7.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.07

stock-summary
Return on Equity

8.02%

stock-summary
Price to Book

0.47